Roche (RHO) Reports Phase III Interim Win in IgAN

Roche said Phase III IMAgINATION met its primary endpoint, with once-monthly sefaxersen showing statistically significant proteinuria reduction vs placebo at week 37 in adults with IgA nephropathy. Safety was consistent with prior data; the study continues to week 105.Material DetailsContext by AI…